• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    6/15/26 5:24:38 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care
    Get the next $TFX alert in real time by email
    8-K
    TELEFLEX INC false 0000096943 0000096943 2026-06-15 2026-06-15
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 15, 2026

     

     

    Teleflex Incorporated

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   1-5353   23-1147939

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    550 E. Swedesford Rd, Suite 400  
    Wayne, PA   19087
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (610) 255-6800

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, par value $1.00 per share   TFX   New York Stock Exchange

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01 Entry into a Material Definitive Agreement

    On June 15, 2026, Teleflex Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.875% senior notes due January 2032 (the “Notes”), pursuant to an indenture, dated as of June 15, 2026 (the “Indenture”), among the Company, the guarantors party thereto (the “Guarantors”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).

    The Notes pay interest semi-annually on January 15 and July 15, commencing on January 15, 2027, at a rate of 5.875% per year, and mature on January 15, 2032.

    Ranking

    The Notes and the guarantees thereof are the Company’s and the Guarantors’ general unsecured senior obligations and rank pari passu in right of payment with all of the Company’s and the Guarantors’ existing and future senior obligations, including the Company’s 4.25% senior notes due 2028, and senior in right of payment to any of the Company’s and the Guarantors’ future subordinated indebtedness. The Notes and the guarantees thereof are effectively subordinated to the Company’s and the Guarantors’ existing and future secured indebtedness, including all outstanding term loans and revolver borrowings under the Company’s credit agreement, to the extent of the value of the assets securing such indebtedness. The Notes and the guarantees are structurally subordinated to all existing and future indebtedness and other claims and liabilities, including preferred stock, of the Company’s subsidiaries that do not guarantee the Notes.

    Guarantees

    The obligations under the Notes are, and will be, fully and unconditionally guaranteed, jointly and severally, by each of the Company’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under the Company’s credit agreement and certain other indebtedness, as further specified in the Indenture.

    Optional Redemption

    At any time prior to January 15, 2029, the Company may on any one or more occasions redeem all or a part of the Notes at a redemption price equal to 100% of the principal amount of the Notes redeemed, plus the greater of (1) 1.0% of the principal amount of the Notes and (2) the excess, if any, of (a) the present value at such redemption date of (i) the redemption price of such note at January 15, 2029 (as set forth in the table appearing below), plus (ii) all required interest payments due on the Notes through January 15, 2029 (excluding accrued but unpaid interest to the redemption date), computed using a discount rate equal to the treasury rate as of such redemption date plus 50 basis points; over (b) the then outstanding principal amount of the Notes (as of, and plus accrued and unpaid interest, if any, to, the date of redemption), subject to the rights of holders of the notes on the relevant record date to receive interest due on the relevant interest payment date.

    On or after January 15, 2029, the Company may on any one or more occasions redeem all or a part of the Notes at the redemption prices (expressed as percentages of principal amount) set forth below, plus accrued and unpaid interest, if any, on the Notes redeemed, to, but not including, the applicable date of redemption, if redeemed during the twelve-month period beginning on January 15 of the years indicated below, subject to the rights of Holders on the relevant record date to receive interest due on the relevant interest payment date:

     

    Year

       Percentage  

    2029

         102.938 % 

    2030

         101.469 % 

    2031 and thereafter

         100.000 % 

    In addition, at any time prior to January 15, 2029, the Company may on any one or more occasions redeem up to 40% of the aggregate principal amount of Notes issued under the Indenture (including any additional notes) at a redemption price equal to 105.875% of the principal amount of the Notes redeemed, plus accrued and unpaid interest thereon, if any, to the applicable redemption date, subject to the right of holders of record on the relevant record date to receive interest due on the relevant interest payment date, with the net cash proceeds of one or more


    equity offerings; provided, that, at least 60% of the aggregate principal amount of Notes originally issued under the indenture (excluding notes held by the Company and its subsidiaries) remains outstanding immediately after the occurrence of such redemption; provided further that each such redemption occurs within 120 days of the date of closing of each such equity offering.

    Change of Control Triggering Event

    If the Company experiences certain change of control events coupled with a downgrade in the ratings of the Notes, the Company must offer to repurchase the Notes at a repurchase price equal to 101% of the principal amount of the Notes repurchased, plus accrued and unpaid interest, if any, to, but not including, the applicable repurchase date.

    Covenants

    The Indenture contains covenants that, among other things, limit the Company’s ability and the ability of its subsidiaries to:

     

      •  

    create certain liens;

     

      •  

    enter into sale leaseback transactions; and

     

      •  

    merge, consolidate, sell or otherwise dispose of all or substantially all of the Company’s assets.

    Events of Default

    The Indenture also provides for events of default which, if any of them occurs, would permit or require the principal of and accrued interest on the Notes to become or to be declared due and payable.

    * * *

    The foregoing description of the Indenture, the Notes and the guarantees is qualified in its entirety by reference to the actual terms of the Indenture and the Notes, copies of which are attached as Exhibits 4.1 and 4.2 hereto and are incorporated by reference herein.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant

    The information set forth in Item 1.01 is incorporated by reference into this Item 2.03.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    4.1    Indenture, dated June 15, 2026, by and among Teleflex Incorporated, the guarantors named therein and U.S. Bank Trust Company, National Association
    4.2    Form of 5.875% Senior Notes due January 2032 (included in Exhibit 4.1)
    104    The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: June 15, 2026

     

    TELEFLEX INCORPORATED
    By:  

    /s/ Daniel V. Logue

    Name: Daniel V. Logue
    Title: Corporate Vice President, General Counsel and Secretary
    Get the next $TFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TFX

    DatePrice TargetRatingAnalyst
    6/8/2026$160.00Neutral → Overweight
    Piper Sandler
    5/8/2026$155.00Sector Perform → Outperform
    RBC Capital Mkts
    4/13/2026$135.00Underperform → Neutral
    BofA Securities
    3/27/2026$128.00Mkt Perform → Outperform
    Raymond James
    1/27/2026$138.00Hold → Buy
    Needham
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    2/28/2025Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A bought $115,860 worth of shares (1,000 units at $115.86), increasing direct ownership by 15% to 7,547 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 6:02:01 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Director Krakauer Andrew A bought $115,250 worth of shares (1,000 units at $115.25), increasing direct ownership by 16% to 7,192 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:15:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Chairman, President & CEO Kelly Liam bought $172,605 worth of shares (1,500 units at $115.07), increasing direct ownership by 3% to 45,267 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    8/7/25 4:14:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold

    Enrollment completed ahead of schedule in BIOMAG™-II Positive four-year BIOMAG™-I results recently reported Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the beginning of enrollment in the BIOMAG™‑III Study (NCT07258290), a landmark global study evaluating the Freesolve™ Resorbable Magnesium Scaffold (RMS). Dr. Itsik Ben-Dor, MedStar Health in Washington, D.C., is the first implanter in the United States (U.S.) in the IDE trial of Freesolve™ RMS. Designed as a pivotal trial to support future regulatory applications, the BIOMAG™‑III Study represents the most comprehensive planned clinical evaluation of Freesolve™ RMS to date. Cha

    6/23/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)

    Persistently Low Target Lesion Failure and No New Cardiac-Related Event Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the four‑year follow‑up data from the First-in-Human BIOMAG™-I Clinical Study (NCT04157153)* presented at the EuroPCR conference in Paris, France by Prof. Jan Torzewski (Klinikverbund Allgäu, Germany). Conducted exclusively across European centers and enrolling 116 patients, the study continues to demonstrate a favorable long‑term safety profile1, with no new cardiac‑related1 events observed between two and four years follow‑up period, establishing the third-generation Freesolve™ Resorbable Magnesium Scaffold (RMS) a

    6/9/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated Announces Pricing of $500 Million Senior Notes Offering

    Teleflex Incorporated (NYSE:TFX) ("Teleflex") announced today that it priced its private offering of $500.0 million aggregate principal amount of 5.875% senior notes due 2032 (the "Notes") at an issue price of 100.000%. The sale of the Notes is expected to close on June 15, 2026, subject to customary closing conditions. The Notes will be guaranteed by each of Teleflex's existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under its credit agreement and certain other indebtedness. Teleflex intends to use the net proceeds from the offering, together with cash on hand, to redeem all of its outstanding 4.625% Senior Notes due 2027 (the "2027 Notes").

    6/1/26 5:40:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teleflex upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Teleflex from Neutral to Overweight and set a new price target of $160.00

    6/8/26 8:30:04 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Teleflex from Sector Perform to Outperform and set a new price target of $155.00

    5/8/26 8:43:10 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex upgraded by BofA Securities with a new price target

    BofA Securities upgraded Teleflex from Underperform to Neutral and set a new price target of $135.00

    4/13/26 9:17:17 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    SEC Filings

    View All

    Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - TELEFLEX INC (0000096943) (Filer)

    6/15/26 5:24:38 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Leadership Update

    8-K - TELEFLEX INC (0000096943) (Filer)

    6/9/26 5:13:16 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Incorporated filed SEC Form 8-K: Other Events, Regulation FD Disclosure

    8-K - TELEFLEX INC (0000096943) (Filer)

    6/1/26 7:59:04 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Randle Stuart A covered exercise/tax liability with 4,054 shares and was granted 5,658 shares, increasing direct ownership by 8% to 21,187 units (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    6/9/26 8:32:30 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    President and CEO Weidman Jason R. was granted 53,983 shares (SEC Form 4)

    4 - TELEFLEX INC (0000096943) (Issuer)

    6/9/26 8:31:33 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Weidman Jason R.

    3 - TELEFLEX INC (0000096943) (Issuer)

    6/9/26 8:30:44 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/14/24 1:28:29 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    11/8/24 10:29:30 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Teleflex Incorporated (Amendment)

    SC 13G/A - TELEFLEX INC (0000096943) (Subject)

    2/14/24 10:04:36 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Financials

    Live finance-specific insights

    View All

    Teleflex Announces Quarterly Dividend

    Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believ

    5/15/26 4:30:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook

    Teleflex Incorporated (NYSE:TFX) (the "Company") today announced financial results for the first quarter ended March 31, 2026. First quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $548.3 million, up 32.3% compared to the prior year period, and up 5.1% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS from continuing operations of $(0.11), compared to $1.14 in the prior year period Adjusted diluted EPS from continuing operations of $1.39, compared to $1.44 in the prior year period 2026 continuing operations guidance summary1 Maintaining GAAP revenue growth guidance range of 14.40% to 15.40% Maintaining pro for

    5/7/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces First Quarter 2026 Earnings Conference Call Information

    Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 7, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available beginning at 11:00 a.m. Eastern Time on May 7, 2026, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

    4/23/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    $TFX
    Leadership Updates

    Live Leadership Updates

    View All

    Teleflex Appoints Jason Weidman as President and CEO

    Proven Industry Leader to Guide Company's Next Chapter of Growth and Value Creation Teleflex Incorporated (NYSE:TFX) today announced that Jason Weidman has been appointed President and Chief Executive Officer, effective June 8, 2026. He will succeed Stuart Randle, who has been serving as Interim President and CEO since January 2026 and will continue as a member of Teleflex's Board of Directors. Mr. Weidman is expected to join the Teleflex Board when he assumes his role as President and CEO. Mr. Weidman is a proven medical technology leader with over 25 years of industry experience and a strong track record of building and scaling businesses globally. He joins Teleflex from Medtronic plc

    4/30/26 6:30:00 AM ET
    $TFX
    Medical/Dental Instruments
    Health Care

    Teleflex Announces Governance Updates

    Michael J. Tokich, Medical Technology Industry Veteran, Nominated as Independent Director; Andrew A. Krakauer Appointed Chairman of the Board Effective Following 2026 Annual Meeting Board to Establish Growth and Operating Committee Company to Commence Share Repurchases Ahead of Schedule Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced several Board and governance updates, including the nomination of Michael J. Tokich to the Board of Directors, its intent to establish a new Growth and Operating Committee of the Board and its plan to commence share repurchases under the Company's previously announced program ahead of schedule. The an

    4/9/26 6:30:00 AM ET
    $MTD
    $STE
    $TFX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Industrial Specialties
    Health Care

    Teleflex Reiterates Commitment to Value Maximizing Strategies and Strong Execution

    Previously Announced Sale Transactions on Track to Close in Second Half of 2026; Expecting $1.8 Billion of Net Proceeds for Buyback and Debt Paydown Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today issued the following statement in response to the press release issued by Irenic Capital Management L.P. ("Irenic"). The Teleflex Board of Directors and management team are committed to acting in the best interests of the Company and its shareholders. Members of the Board and management team met with Irenic at their request on March 19, 2026, to better understand their views and underscore the Company's commitment to maximizing value for shareholders.

    3/27/26 12:57:00 PM ET
    $TFX
    Medical/Dental Instruments
    Health Care